{
    "clinical_study": {
        "@rank": "114232", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PO administration"
            }, 
            {
                "arm_group_label": "DA-8031 dose 1", 
                "arm_group_type": "Experimental", 
                "description": "PO administration"
            }, 
            {
                "arm_group_label": "DA-8031 dose 2", 
                "arm_group_type": "Experimental", 
                "description": "PO administration"
            }, 
            {
                "arm_group_label": "DA-8031 dose 3", 
                "arm_group_type": "Experimental", 
                "description": "PO administration"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the efficacy and safety of DA-8031 and to decide the\n      optimal dose of DA-8031 in male patients with premature ejaculation after oral\n      administration on-demand.\n\n      The investigators hypothesized that newly-developed DA-8031 would effect in delaying\n      ejaculation in patients with premature ejaculation (PE).\n\n      Design:\n\n      Placebo-controlled, Randomized, Double-blind, Double-dummy, Parallel group, Fixed dose\n      design"
        }, 
        "brief_title": "Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Premature Ejaculation", 
        "condition_browse": {
            "mesh_term": "Sexual Dysfunctions, Psychological"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patients aged with premature ejaculation for more than 6 months.\n\n          -  PEDT score \u2265 11\n\n        Exclusion Criteria:\n\n          -  IIEF-EF domain \u2264 21\n\n          -  Serum Creatinine \u2265 2.5 mg/dl\n\n          -  AST, ALT > 3*Upper limit of normal\n\n          -  Subjects with hypotension(SBP/DBP<90/50mmHg) or uncontrolled\n             hypertension(SBP/DBP>180/100mmHg)\n\n          -  Subjects with chronic depression, psychiatric or schizophrenia,\n\n          -  Subjects with alcohol, drug or substance abuse"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798667", 
            "org_study_id": "DA8031_PE_II"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DA-8031 dose 1", 
                    "DA-8031 dose 2", 
                    "DA-8031 dose 3"
                ], 
                "intervention_name": "DA-8031", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo of DA-8031, undistinguishable", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 14, 2013", 
        "location": {
            "contact": {
                "last_name": "Sung Won Lee"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Double-dummy, Placebo-controlled, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 After Oral Administration in Male Patients With Premature Ejaculation", 
        "overall_contact": {
            "email": "drswlee@skku.edu", 
            "last_name": "Sung Won Lee"
        }, 
        "overall_official": [
            {
                "affiliation": "Seoul St. Mary's Hospital", 
                "last_name": "Sae Woong Kim", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Guro Hospital", 
                "last_name": "Du Geon Moon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pusan National University Hospital", 
                "last_name": "Nam-Cheol Park", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Jae-Seung Paick", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Tai-Young Ahn", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Sung Won Lee", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yeongnam University Hospital", 
                "last_name": "Ki Hak Moon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Kwangsung Park", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonbuk National University Hospital", 
                "last_name": "Jong Kwan Park", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kangdong Sacred Heart Hospital", 
                "last_name": "Dae Yul Yang", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "average IELT change", 
            "safety_issue": "No", 
            "time_frame": "From 0 week(baseline) to 8 week(end of treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "PEP(Primary ejaculation profile), PGI(Patient-reported global impression)", 
            "measure": "PEP, PGI", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}